Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26638041 | 1.00 | ACACB (0.40) | ACACBHPGDCYP11B2CYP1A2CYP2C9 | |
| SCHEMBL26637899 | 0.91 | CYP1A2 (0.41) | ACACBCYP1A2CYP2C9CYP2C19GHSR | |
| SCHEMBL26637901 | 0.91 | CYP1A2 (0.41) | ACACBCYP1A2CYP2C9CYP2C19GHSR | |
| SCHEMBL26638244 | 0.89 | ALDH1A1 (0.48) | HPGDKMT2ACRHBPCRHR2ALDH1A1 | |
| SCHEMBL26638243 | 0.89 | ALDH1A1 (0.48) | HPGDKMT2ACRHBPCRHR2ALDH1A1 | |
| SCHEMBL26638079 | 0.82 | NR1D1 (0.40) | HPGDCYP1A2CYP2C9CYP2C19GHSR | |
| SCHEMBL26638081 | 0.82 | NR1D1 (0.40) | HPGDCYP1A2CYP2C9CYP2C19GHSR | |
| SCHEMBL26638193 | 0.81 | LMNA (0.45) | ACACBHPGDKMT2ACRHBPCRHR2 | |
| SCHEMBL26638191 | 0.81 | LMNA (0.45) | ACACBHPGDKMT2ACRHBPCRHR2 | |
| SCHEMBL4749076 | 0.75 | EPHX2 (0.53) | ACACBCYP11B2CYP2C9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | claimed |
| EP-3986873-B9 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-05-29 | — | — | EP | claimed |
| EP-3986873-B1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2023-11-15 | — | — | EP | claimed |
| US-20220274938-A1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2022-09-01 | — | — | US | claimed |
| EP-3986873-A1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | claimed |
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | disclosed |
| EP-3986873-B9 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-05-29 | — | — | EP | disclosed |
| EP-3986873-B1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2023-11-15 | — | — | EP | disclosed |
| US-20220274938-A1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2022-09-01 | — | — | US | disclosed |
| EP-3986873-A1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274938-A1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | RYR1, CACNB1, CACNA1D | ACACB 2270/4885HPGD 4632/4885CYP11B2 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.